Skip to main navigation Skip to search Skip to main content

Neuro-Mesenchymal Interaction Mediated by a β2-Adrenergic Nerve Growth Factor Feedforward Loop Promotes Colorectal Cancer Progression

  • Hiroki Kobayashi
  • , Tadashi Iida
  • , Yosuke Ochiai
  • , Ermanno Malagola
  • , Xiaofei Zhi
  • , Ruth A. White
  • , Jin Qian
  • , Feijing Wu
  • , Quin T. Waterbury
  • , Ruhong Tu
  • , Biyun Zheng
  • , Jonathan S. Labella
  • , Leah B. Zamechek
  • , Atsushi Ogura
  • , Susan L. Woods
  • , Daniel L. Worthley
  • , Atsushi Enomoto
  • , Timothy C. Wang

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer-associated fibroblasts (CAF) and nerves, components of the tumor microenvironment, have each been shown to directly promote gastrointestinal cancers. However, it remains unknown whether these cells interact with each other to regulate cancer progression. We found that in colorectal cancer, norepinephrine induces ADRB2 (β2-adrenergic receptor)–dependent nerve growth factor (NGF) secretion from CAFs, which in turn increases intratumor sympathetic innervation and norepinephrine accumulation. Adrenergic stimulation accelerates colorectal cancer growth through ADRA2A/Gi-mediated activation of Yes-associated protein (YAP). NGF from CAFs directly enhances colorectal cancer cell growth via the phosphatidylinositol-3kinase/AKT pathway. Treatment with a tropomyosin receptor kinase (TRK) inhibitor decreased YAP and AKT activation and colorectal cancer progression in mice. In human colorectal cancer, high NGF expression is associated with mesenchymal-like tumor subtype and poor patient survival. These findings suggest a central role for reciprocal CAF–nerve cross-talk in promoting colorectal cancer progression. Blocking this feedforward loop with a TRK inhibitor may represent a potential therapeutic approach for colorectal cancer.

Original languageEnglish
Pages (from-to)202-226
Number of pages25
JournalCancer Discovery
Volume15
Issue number1
DOIs
Publication statusPublished or Issued - 1 Jan 2025

ASJC Scopus subject areas

  • Oncology

Cite this